News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biocept, Inc. to Present at the American Association for Cancer Research Annual Meeting on Ability of its CEE-SelectorTM Technology to Enhance the Sensitivity of Sequencing for Rare Mutation Detection



4/5/2013 6:30:37 AM

Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced that Lyle Arnold, Ph.D., Senior Vice President, R&D and Chief Scientific Officer, is presenting a poster at the 103rd Annual Meeting of the American Association for Cancer Research, being held in Washington DC April 6 – April 10, on improvements to the company’s ultra-sensitive mutation detection technology, CEE-SelectorTM, that significantly increase the sensitivity of standard or next generation sequencing.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES